Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.